IBSA, as a signatory of the World Anti-Doping Code, fully supports its purpose which is to:
- Protect the athlete's fundamental right to participate in doping-free sport and thus promote health, fairness and equality for athletes worldwide;
- Ensure a harmonized, coordinated and effective anti-doping programme on the international and national level with regard to detection, deterrence and prevention of doping.
IBSA does this through enforcing its anti-doping rules that are in full compliance with the World Anti-Doping Code.
Links to key anti-doping documents:
- Link to IBSA Anti-Doping rules
- Link to WADA Anti-Doping Code
- Link to WADA List of Prohibited Substances and Methods 2020
- Link to WADA List of Prohibited Substances and Methods 2020
- Link to WADA list of Prohibited Substances and Methods 2020
- Link to IBSA Therapeutic Use Exemption Form - Word
IBSA Anti-Doping Rules
IBSA Anti-Doping Rules apply to athletes, competitors, players and their support staff participating in the activities or events of IBSA or any of its national member organisations. Consequently, athletes competing in events organised under the auspices of IBSA may be subject to doping control testing at any time, with or without advance notice.
Therapeutic Use Exemptions (TUEs)
Athletes, like all people, may have illnesses or conditions that require them to take particular medications or undergo procedures. If the medication or method an athlete is required to take/use to treat an illness or condition is included in the World Anti-Doping Agency’s (WADA) Prohibited List, a Therapeutic Use Exemption (TUE) may give that athlete the authorisation to take a substance or use a method that is prohibited.
Applications for TUEs are reviewed by a panel of experts, the TUE Committee (TUEC), who may give such permission.
Download the full IBSA guidance for TUEs
Download the IBSA TUE Application Form in PDF
Download the IBSA TUE Application form in Word
The education of athletes, coaches and medical practitioners is critical to the success of any anti-doping programme. Below are a variety of resources to assist all in understanding the processes of doping control and the implications of doping in sport:
• WADA Quiz - Test your knowledge of anti-doping
• WADA Doping Control Leaflet (English)
• WADA Dangers of Doping Leaflet (English)
• WADA Dangers of Doping Leaflet (Other languages)
• WADA Doping Control Video
IBSA Anti-Doping Committee
Mrs. Hela Kouki Chaouachi (chair)
Mr. Halim Jebali (member)
Mrs. Sana Khelifa (legal advisor)
Mrs. Raja Anane Touzri (member)
Mrs. Daniela Drogge (administrator)
Should you have any questions or need further clarification, please do not hesitate to contact email@example.com
IBSA Testing Pool
In the fight against doping, the anti-doping control system has a critically important role to play. These controls not only occur during competition but, in order to combat doping effectively and preventatively, also take place out-of-competition.
While any athlete may be randomly tested, IBSA - according to procedures outlined by WADA - largely focuses its testing on athletes taking part or susceptible to taking part in top-level international competition.
In accordance with WADA’s International Standards for Testing & Investigation, IBSA maintains lists of such players, which are referred to as the IBSA Testing Pool and defined as the pool of highest-priority athletes established separately at the international level by IBSA. They are subject to focused In-Competition and Out-of-Competition Testing as part of IBSA's test distribution plan and therefore are required to provide whereabouts information as provided in Article 5.6 of the Code and the WADA International Standard for Testing and Investigations (2015)
WADA information on Doping Control Forms (DCFs) and Therapeutic Use Exemption (TUE) (effective as of June 1st 2016)
Mandatory Use of ADAMS for DCFs and TUEs
In order to reinforce the existing requirements of the 2015 World Anti-Doping Code (Code) (Article 14.5); as well as the International Standards for Testing and Investigations (ISTI) (Article 4.9.1b) and Therapeutic Use Exemptions (ISTUE) (Article 5.4); and, to ensure the transparency of all signatories’ anti-doping programs, the Foundation Board of the World Anti-Doping Agency (WADA) decided at its meeting on 12th May 2016 that:
- Given that it is a mandatory requirement under the Code and the ISTI to enter all Doping Control Forms (DCFs) and under the ISTUE to enter all Therapeutic Use Exemption (TUE) decisions into ADAMS, all DCFs and TUE decisions shall be entered into ADAMS no later than 15 business days after sample collection or receipt of a TUE decision; and
- Failure to do so will result in a declaration of non-compliance, in accordance with the ISO certified WADA process for non-compliance.
This decision took effect 1 June 2016.
The TUE form
that is mandatory when requesting a TUE can be found in the documents section of this webpage.
WADA’s access to DCFs and TUE information is a key element to ensure effective monitoring of ADOs’ anti-doping programs. A key recommendation of WADA’s Independent Commission which exposed widespread doping in Russian athletics, was for WADA to reiterate to all signatories that they are obliged to “provide complete and timely data for ADAMS”. WADA’s Athlete Committee also strongly supports this requirement.
DCFs must be entered into ADAMS to enable a meaningful steroidal and hematological Athlete Biological Passport's program to operate globally; to facilitate coordinated test distribution planning; and, to avoid unnecessary duplication in testing by ADOs. Despite this already being a requirement of the Code and ISTI, only 60% of DCFs globally were entered into ADAMS in 2015.
It is equally important that information about TUEs be made available via ADAMS. This is necessary in order to allow WADA to fulfill its responsibilities under Article 14.5 of the Code with respect to the sharing of data and coordination of anti-doping activities.
ADOs that require assistance with the entry of the required information into ADAMS are invited to contact WADA via ADAMS@wada-ama.org
IBSA Anti-Doping Statistics
In the last three years (2017-2019), the scale of testing under IBSA as the Testing Authority increased from 59 tests (all in competition) in 2017, to 109 tests (including 94 in competition) in 2018. In 2019, 165 tests were carried out, including 153 in competitions.
Other 18 in competition tests were performed at IBSA events under IBSA as Result Managment only.
In fact, all IBSA sanctioned and approved events were subject to doping controls in 2019.
Tests were also diversified implementing out of competition testing besides in competition ones, as well as blood testing in addition to urine testing.
In 2019, six IBSA sports disciplines were tested in and/or out of competition under IBSA as Testing Authority and Result Managment Authority:
Football 5-a-side (44 incl. 3 blood tests),
Goalball (35 incl. 1 blood test),
IBSA Powerlifting (10),
Showdown (4) and,
Nine-pin bowling (2).
Compared to 2018 where IBSA testing program revealed 3 AAFs (1 ADRV and 2 no - ADRVs), in 2019, it revealed 6 (six) Adverse Analytical Findings (AAFs) among them three (3) were reviewed and decided not to be Anti-Doping Rule Violations, whereas the 3 (three) others are actually under review as per IBSA Procedures Guide for Result Management
, compliant with WADA Code and applicable guidelines.
Anti-Doping Rule Violations
In 2017, one analytical ADRV (2.1.) was established on a para-judo athlete Nurmetova Tursunpashsha tested in competition. Her urine samples revealed use of Furosemide, a specified prohibited substance from S5. Diuretics and masking agents.
IBSA disciplinary committee decided her ineligibility for four years (from May 27th, 2017 to May 26th, 2021).
1 AAF registered in 2018 and 3 AAFs registered in 2019 remain under review.
Photo album featuring images of IBSA's Anti-Doping activities.